
	Eleven Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, is engaged in the discovery and development of protein therapeutics to treat eye diseases primarily in the United States. The company develops its therapeutics through AMP-Rx, a proprietary protein engineering platform. Its principal product candidate is EBI-005, a novel IL-1 receptor antagonist for the topical treatment of dry eye disease and allergic conjunctivitis. The company&rsquo;s preclinical product candidates include EBI-029, a novel inhibitor of the cytokine IL-6 for the treatment of certain retinal diseases, such as DME; and EBI-028, a novel inhibitor of the cytokine IL-17 for the treatment of uveitis, and other diseases of the back of the eye, such as dry AMD. Eleven Biotherapeutics, Inc. has a collaboration and license agreement with ThromboGenics N.V. to identify protein or peptide therapeutics that directly modulate any of a specified set of targets in a novel pathway in retinal disease. The company was founded in 2008 and is based in Cambridge, Massachusetts.
